Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage 1 and Stage 2 FAP participants with the following:~  1. NIS score within protocol criteria~ 2. Documented transthyretin variant by genotyping~ 3. Documented amyloid deposit by biopsy~* Females of child-bearing potential must use appropriate contraception and be non-pregnant and non-lactating. Males engaging in relations of child-bearing potential are to use appropriate contraception~Exclusion Criteria:~* Low Retinol level at screen~* Karnofsky performance status ≤50~* Poor Renal function~* Known type 1 or type 2 diabetes mellitus~* Other causes of sensorimotor or autonomic neuropathy (for example, autoimmune disease)~* If previously treated with Vyndaqel®, will need to have discontinued treatment for 2 weeks prior to Study Day 1. If previously treated with Diflunisal, will need to have discontinued treatment for 3 days prior to Study Day 1~* Previous treatment with any oligonucleotide or siRNA within 12 months of screening~* Prior liver transplant or anticipated liver transplant within 1 year of screening~* New York Heart Association (NYHA) functional classification of ≥3~* Acute Coronary Syndrome or major surgery within 3 months of screening~* Known Primary or Leptomeningeal Amyloidosis~* Anticipated survival less than 2 years~* Any other conditions in the opinion of the investigator which interfere with the participant participating in or completing the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 82 Years
- Healthy Volunteers: f

Study Arms:
- Inotersen (Type: ACTIVE_COMPARATOR): 300 mg inotersen administered subcutaneously (SC) 3 times on alternate days in the first week and then once-weekly for 64 weeks
- Placebo (Type: ACTIVE_COMPARATOR): Placebo administered SC 3 times on alternate days in the first week and then once-weekly for 64 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).